CD274 and neoplasm: Tumor PD‐L1 expression measured by immunohistochemistry (IHC), either assessed on tumor cells, infiltrating immune cells or a combination is the main biomarker for selecting patients to PD1/PD‐L1 inhibition in mTNBC [1, 2].